Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.

Silver M, Rusk A, Phillips B, Beck E, Jankowski M, Philibert J, Hahn K, Hershey E, McKeegan E, Bauch J, Krivoshik A, Khanna C.

J Vet Intern Med. 2012 Mar-Apr;26(2):349-54. doi: 10.1111/j.1939-1676.2012.00892.x. Epub 2012 Feb 28.

2.

Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma.

Rusk A, Cozzi E, Stebbins M, Vail D, Graham J, Valli V, Henkin J, Sharpee R, Khanna C.

Clin Cancer Res. 2006 Dec 15;12(24):7456-64.

3.

Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma.

Vail DM, Husbands BD, Kamerling SG, Simpson H, Kurzman ID, McDonnell A.

J Vet Intern Med. 2012 May-Jun;26(3):608-13. doi: 10.1111/j.1939-1676.2012.00896.x. Epub 2012 Mar 9.

4.

High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M.

Clin Cancer Res. 2006 Sep 1;12(17):5190-8.

5.

Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma.

Vail DM, Thamm DH, Reiser H, Ray AS, Wolfgang GH, Watkins WJ, Babusis D, Henne IN, Hawkins MJ, Kurzman ID, Jeraj R, Vanderhoek M, Plaza S, Anderson C, Wessel MA, Robat C, Lawrence J, Tumas DB.

Clin Cancer Res. 2009 May 15;15(10):3503-10. doi: 10.1158/1078-0432.CCR-08-3113. Epub 2009 May 5.

6.

Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.

Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ.

Clin Cancer Res. 2005 Sep 15;11(18):6615-24.

7.

Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma.

Sahora AI, Rusk AW, Henkin J, McKeegan EM, Shi Y, Khanna C.

J Vet Intern Med. 2012 Sep-Oct;26(5):1169-76. doi: 10.1111/j.1939-1676.2012.00966.x. Epub 2012 Jul 21.

8.

Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.

Jorgensen TJ, Tian H, Joseph IB, Menon K, Frost D.

Cancer Chemother Pharmacol. 2007 May;59(6):725-32. Epub 2006 Sep 12.

PMID:
16967299
9.

A phase II study of ABT-751 in patients with advanced non-small cell lung cancer.

Mauer AM, Cohen EE, Ma PC, Kozloff MF, Schwartzberg L, Coates AI, Qian J, Hagey AE, Gordon GB.

J Thorac Oncol. 2008 Jun;3(6):631-6. doi: 10.1097/JTO.0b013e318174e01f.

PMID:
18520803
10.

A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.

Fox E, Maris JM, Widemann BC, Meek K, Goodwin A, Goodspeed W, Kromplewski M, Fouts ME, Medina D, Cho SY, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM.

Clin Cancer Res. 2006 Aug 15;12(16):4882-7.

11.

The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.

Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML.

Clin Cancer Res. 2006 May 1;12(9):2834-40.

12.

Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.

Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C.

Clin Cancer Res. 2006 Dec 15;12(24):7444-55.

13.

Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.

Selting KA, Wang X, Gustafson DL, Henry CJ, Villamil JA, McCaw DL, Tate D, Beittenmiller M, Garnett C, Robertson JD.

J Vet Intern Med. 2011 Jul-Aug;25(4):909-15. doi: 10.1111/j.1939-1676.2011.0727.x. Epub 2011 May 12.

14.

An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs.

Fiocchi SC, Selting KA, Rosenberg MP, Kolli P, Lenaz G, Henry C.

J Vet Intern Med. 2011 Jul-Aug;25(4):897-902. doi: 10.1111/j.1939-1676.2011.0752.x. Epub 2011 Jul 7.

15.

Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors.

Knapp DW, Richardson RC, Bottoms GD, Teclaw R, Chan TC.

Cancer Chemother Pharmacol. 1992;29(3):214-8.

PMID:
1733554
16.

Use of 3'-deoxy-3'-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma.

Lawrence J, Vanderhoek M, Barbee D, Jeraj R, Tumas DB, Vail DM.

Vet Radiol Ultrasound. 2009 Nov-Dec;50(6):660-8.

PMID:
19999354
17.
18.

A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.

Sawka CA, Shepherd FA, Franssen E, Brandwein J, Dotten DA, Routy JP, Walker IR, St-Louis J, Taylor M, Arts K, Crump M, Foote M.

Biotechnol Annu Rev. 2005;11:381-9.

PMID:
16216784
19.

Evaluation of single-agent mitoxantrone as chemotherapy for relapsing canine lymphoma.

Lucroy MD, Phillips BS, Kraegel SA, Simonson ER, Madewell BR.

J Vet Intern Med. 1998 Sep-Oct;12(5):325-9.

20.

Radiotherapy in the management of localized mucocutaneous oral lymphoma in dogs: 14 cases.

Berlato D, Schrempp D, Van Den Steen N, Murphy S.

Vet Comp Oncol. 2012 Mar;10(1):16-23. doi: 10.1111/j.1476-5829.2011.00270.x. Epub 2011 Apr 21.

PMID:
22236033
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk